Chronic Pain News and Research

RSS

$Full clinical trial feasible in refractory chronic angina pectoris$

Full clinical trial feasible in refractory chronic angina pectoris

Results of the world's first publicly funded randomized controlled clinical trial of spinal cord stimulation, being presented today at the 12th World Congress of the International Neuromodulation Society, conclude that a fully powered clinical trial is feasible in refractory chronic angina pectoris, a disabling and persistent chronic pain condition.

10 Jun 2015

Stem cell transplant restores sensory functions in injured spinal cord

New research from Uppsala University shows promising progress in the use of stem cells for treatment of spinal cord injury. The results, which are published in the scientific journal Scientific Reports, show that human stem cells that are transplanted to the injured spinal cord contribute to restoration of some sensory functions.

10 Jun 2015

Study suggests direct biophysical link between chronic pain, depression and anxiety

Brain inflammation caused by chronic nerve pain alters activity in regions that regulate mood and motivation, suggesting for the first time that a direct biophysical link exists between long-term pain and the depression, anxiety and substance abuse seen in more than half of these patients, UC Irvine and UCLA researchers report.

9 Jun 2015

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio Pharmaceuticals, Inc. today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion in the treatment of osteoarthritis in the knee.

9 Jun 2015

Boston Scientific announces European launch of Precision Novi SCS System

Boston Scientific announces the European launch of the Precision Novi Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available.

5 Jun 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

4 Jun 2015

New study reports that poor sleep habits increase pain in knee OA

A new study reports that patients with knee osteoarthritis (OA) who have poor sleep habits display greater central sensitization--an amplification of clinical pain. Findings published in Arthritis Care & Research, a journal of the American College of Rheumatology, further show OA patients who catastrophize--consumed by thoughts of pain--had increased central sensitization that was associated with greater clinical pain.

4 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

BioDelivery Sciences secures additional $20.7M in gross debt funding from MidCap Financial

BioDelivery Sciences International, Inc. announced today that it has secured an additional $20.7 million in gross debt funding from MidCap Financial to bring BDSI's total outstanding debt with MidCap to $30 million in a single senior secured loan.

1 Jun 2015

International Neuromodulation Society invites media to satellite-event news briefing before 12th World Congress

Representatives of the news media are invited to a satellite-event news briefing at 11 a.m. on June 6, 2015 before the International Neuromodulation Society 12th World Congress in Montreal.

1 Jun 2015

BioDelivery Sciences calls for new treatment options for opioid addiction

As the rate of opioid abuse soars to new levels, growing recognition of the problem is garnering unprecedented media attention—as well as motivating innovative new approaches to better treatment.

30 May 2015

Canadian researchers shed light on molecular dynamics of chronic pain

Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain.

27 May 2015

First commercial procedure performed using Senza system for delivering Nevro's HF10 therapy

Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy.

24 May 2015

DyAnsys' new non-narcotic treatment solution may provide relief to chronic pain sufferers

Chronic pain sufferers may find relief with a new, safe and effective non-narcotic treatment solution released by medical device maker DyAnsys, Inc. The company announced today that the four-piece system will be available in select doctors' offices and pain management centers.

19 May 2015

Fibromyalgia now considered as a lifelong central nervous system disorder

Fibromyalgia is the second most common rheumatic disorder behind osteoarthritis and, though still widely misunderstood, is now considered to be a lifelong central nervous system disorder, which is responsible for amplified pain that shoots through the body in those who suffer from it.

18 May 2015

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

The American Pain Society today honored the recipients of its annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers. Five multidisciplinary pain programs were recognized.

15 May 2015

APS announces recipients of prestigious achievement awards during annual scientific meeting

The American Pain Society (APS), www.americanpainsociety.org, today announced the recipients of its prestigious achievement awards during the organization's annual scientific meeting.

14 May 2015

Nevro Q1 revenue increases 45% to $9.7 million

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015.

11 May 2015

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system.

10 May 2015

Specific brain chemical may play role in promoting chronic pain

A chemical in the brain typically associated with cognition, movement and reward-motivation behavior -- among others -- may also play a role in promoting chronic pain, according to new research at The University of Texas at Dallas.

7 May 2015